# A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

> **NCT07328009** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 350 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Regorafenib (BAY 73-4506)
- **DRUG:** Tislelizumab+TKI
- **DRUG:** HAIC+TKI
- **DRUG:** HAIC + Tislelizumab+TKI
- **DRUG:** QL1706+TKI
- **DRUG:** HAIC + QL1706+TKI
- **DRUG:** TUDCA + Camrelizumab+TKI
- **DRUG:** XELOX + QL1706+TKI
- **DRUG:** XELOX + Tislelizumab+TKI

## Key facts

- **NCT ID:** NCT07328009
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2029-01-15
- **Final completion:** 2029-01-15
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328009, "A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07328009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*